Ausgewählte Transaktionen
To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle.
Please find below selected transactions completed by WINDOME BANKING PARTNERS‘ employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023).
Exclusive Advisor in Divestiture of Oncology Molecular Diagnostics Medtech Oncotech to Exiqon.
Exclusive Advisor in Divestiture of Specialty Dermatology Company CollaGenex Pharmaceuticals (NASDAQ-listed CGPI) to Galderma SA.
Exclusive Financial Advisor to NASDAQ-listed Exelixis (EXEL) in completing the divestiture of their subsidiary CRO Artemis GmbH to Taconic (TAC).
Exclusive Financial Advisor in Acquisition of Excel-Tech, a developer of electro-diagnostic systems used in monitoring neurological problems.
Exclusive Financial Advisor in Divestiture of US instrumentation medtech NanoDrop Technologies to ThermoFisher.
Exclusive Financial Advisor in Divestiture of Esprit Pharma to Allergan.
Exclusive Financial Advisor in Divestiture of US biotech Renovis to Evotec AG, Hamburg in a reverse merger transaction.
Acquisition of global rights to the Belgian Biotech Ablynx’s nanobody technology platform, global licensing agreement across several therapeutic areas.
Divestiture of Boehringer Ingelheim Do Brasil Química e Farmacêutica Ltda’s assets related to the Finn family of brands to Monte Cristalina SA.
Divestiture of Toride (near Tokyo) facility, Boehringer Ingelheim dedicated plant for the manufacturing of ampoules, to HauptPharma AG, Berlin and concurrent entry into a long-term toll manufacturing agreement.
Acquisition of the over-the-counter („OTC“) Zantac anti-ulcerant gastrointestinal products from Johnson & Johnson (J&J).
Divestiture of Toyama facility, Boehringer Ingelheim’s dedicated plant for the manufacturing of lyophilized solutions to Yamanouchi-Fujisawa (now Astellas) and concurrent entry into a long-term toll manufacturing agreement via carve-out (“Bunkatsu procedure”).